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Abstract 
Effects of the leaf extract Ginkgo 
biloba, ginkgolides A and B, and the 
amino acid taurine (2-aminoethane 
sulfonic acid) on platelet aggregation was 
studied. All potential anitcoagulants were 
incubated in day one platelet-rich plasma 
and subjected to various agonist-induced 
clotting and tests and other measures of 
platelet viability. G. biloba extract and its 
respective ginkgolides had no effect on 
platelet aggregation in response to ADP 
and thrombin, while taurine exhibited 
prolongation of thrombin time (TT) and 
reduced thrombin-induced aggregation 
by 10%. Taurine prolonged time of 
initial clot formation on throm-
bolestographic tests, but overall clot 
viability remained unaffected. These data 
suggest that G. biloba and its active 
ginkgolides do not inhibit platelet 
aggregation induced by ADP and 
thrombin, while taurine mildly inhibits 
thrombin-induced platelet aggregation. 
These findings correlate with taurine's 
osmoregulatory and cryoprotective 
properties and indicate a role as a 
hemostasis stabilizer rather than an 
anticoagulant. Possible mechanism of 
taurine action is suggested. 
Abbreviations: EGb 761, Ginkgo bi/oba 
extract; GA, ginkgolide A; GB, ginkgolide 
B; PT, prothrombin time; APTT, activated 
partial thromboplastin time; TT, thrombin 
time; ESC, extent of shape change; HSR, 
hypotonic shock response; PRP, platelet-
rich plasma; PPP, platelet-poor plasma. 
Introduction 
Leaves from the plant Ginkgo biloba 
have been an integral part of Chinese 
herbal medicine for over 5,000 years, but it 
is only fairly recently that Western 
medicine has acknowledged it's 
physiological effects and pharmacological 
implications. Similarly, taurine, an amino 
acid ubiquitous throughout the animal 
kingdom, has an ancient evolutionary 
history, but only in recent decades has it 
stimulated interest in the biomedical 
community. Many biological effects of 
G. bi/oba have been reported in current 
literature including cerebrovascular and 
memory enhancement, 1,2 antioxidant 
action,>' 3 neurotransmitter stimulation,>' 3 
and inhibition of platelet aggregation. 1-5 
Taurine exerts a similarly copious influence 
on biological phenomena with effects 
including bile conjugation, 68 
osmoregulation, 6,8-9 membrane 
stabilization, 6,9 cellular calcium 
modulation, 6,10 anti oxidation , 6,7 and 
inhibition of platelet aggregation.6, 10-13 
G. biloba and taurine's influence on 
platelet aggregation is the exclusive focus 
of this study. 
The number of studies on G. biloba is 
rapidly increasing, due in no small part to 
the American public's increasing 
fascination with complimentary and 
alternative medicine and accordingly, the 
traditional healer's sensitivity to the needs 
of his or her patients. Due to its 
classification as a supplement, G. biloba 
extract (EGb 761), the commercially 
available form of the herb, is not regulated 
by the FDA, and because it can be 
purchased over-the counter, adverse side 
effects and/or drug-interactions are usually 
not considered before taking the 
supplement. Similarly, physicians may not 
realize their patients are using herbal 
extracts until a potentially dangerous 
situation presents itself, such as in 
situations of perioperative care.3 
EGb 761 is purified and concentrated 
1 :50 (extract: leaves) and consists of 24% 
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flavonoid glycosides compounds, 2.4% 
bilobalide, and 2, 0.8, and 1 % ginkgolides 
A, B, and C, respectively (Fig. 1). The 
extract is processed as a powder and 
manufactured in pill-form by various 
pharmaceutical companies. 
Figure 1. Chemical structures of Ginkgo biloba 
extract (EGb 761) constituents 
_. 
-
A. Glucorhamnoside ester of 
kaempferol (R=H) and quercetin 
(R=OH): Flavenoid fraction 
B. Ginkglodides and bilobalide: 
Terpene lactone fraction 
GinkgoJide A: R=OH, R =H, R =H 
Ginkgolide B: R=OH, R'=OH, 
R"=H 
Ginkgolide C R=OH, R'=OH, 
R"=OH 
Taurine (Fig. 2) has been drawing the 
attention of researchers since it was first 
isolated from the bile of the ox that carries 
its name (Bos taurus). A quick glance at its 
phylogenic distribution and physiological 
influence reveals why. Taurine is present in 
surprisingly high concentrations in algae 
and in the majority of the animal kingdom, 
including arthropods. Except for trace 
amounts, taurine is not found in the 
bacterial and plant kingdoms, mostly due to 
the fact that such organisms possess a cell 
wall and are less likely in need of the 
osmoregulatory protection taurine provides. 
Figure 2. Chemical structure of taurine 
(2-aminoethane sulfonic acid) 
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Taurine is not utilized in protein synthesis 
but rather is found as a free ?-amino acid in 
plasma and in tissues, with highest 
concentrations found in the excitable 
tissues of the heart, brain, and retina.6, 8 
It is also found in increasingly high 
concentrations in platelets. Taurine is 
extremely important in mammalian 
developmen.t, and dietary deficiencies have 
been linked to pathological conditions such 
as cardiomyopathy, retinal degeneration, 
growth retardation, hypercholesterolemia, 
hepatic disorders, and cystic fibrosis.14 
Taurine's developmental importance is 
reinforced by the fact that since 1984 the 
U.S. Department of Agriculture has 
sponsored addition of taurine to human 
infant formulas. IS Virtually all infant 
formula manufacturers worldwide now 
add taurine to their products. 
Another interesting aspect of taurine's 
role in physiological phenomena is its little 
explored or understood role in hibernation 
and freeze tolerance. Hatchlings of the 
painted turtle Chrysemys picta marginata 
are the highest vertebrate life known to 
tolerate the natural freezing of extracellular 
body fluids during winter hibernation. 
When exposed to sub-optimal temperatures, 
it has been shown that the total amino acid 
pool increases 2.25-fold in the liver, 
muscle, and blood, with taurine accounting 
for 52% of this increase. 16 Elevated levels 
of GABA and taurine have been detected 
during hibernation-induced hypothermia in 
hedgehogs,17 and it has been shown that in 
cold acclimation of garter snakes 
(Thamnophis sp.), plasma levels of all 
amino acids except taurine significantly 
decrease, while taurine itself increases in 
concentration.6 Such research has provided 
an impetus for studying taurine's role in 
cryopreservation, and it has recently been 
shown that taurine pretreatment and its 
continued presence during islet 
cryropreservation impoves post-thawing 
viable recovery of islets. 18 
Because of the significant increase in 
plasma taurine levels exhibited by several 
species during hibernation, a period during 
which the cardiovascular system becomes 
sluggish, resulting in decreased blood flow 
and increased risk of intravascular 
thrombus formation, taurine's role as a 
potential anticoagulant or hemostatic 
stabilizer is probable. It has already been 
shown that during hibernation in the frog 
Ratna tigrina clotting tests indicate 
prolongation of several hemostatic factors 
including whole blood clotting time, plasma 
recalcification time, cephalin time, and 
prothrombin time. 19 
While differing markedly in chemical 
structure and mechanism of action, EGb 761 
and taurine both effect similar biological 
processes, notably platelet aggregation. The 
mechanism of EGb 761 ' s inhibitory action 
in the aggregation response has been linked 
to the inhibition of Platelet Activation 
Factor. It has also been linked to inhibition 
of aggregation induced by oxidative stress, 
with ginkgolides A and B of the terpene 
fraction exerting the greatest inhibitory 
effect.l~3 Taurine's inhibition of platelet 
aggregation is associated with its effects on 
intercellular calcium ion translocation, but a 
universally agreed upon mechanism has yet 
to be proposed. 
While several studies have addressed 
G. biloba and taurine's inhibitory effects on 
platelet aggregation in vitro, a direct 
comparison of both compounds and their 
effects on platelet aggregation and other 
factors of hemostasis remains to be studied. 
EGb 761, ginkgolides A and B, and taurine 
were examined in relation to their effects 
on aggregation of platelet rich plasma 
through agonist-induced lumi-aggregation 
and thrombelastography methods with the 
goal of contributing to this understanding. 
Materials and Methods 
Materials 
G. biloba leaf extract (standardized to 
24% flavonoid glycosides, 2.4% bilobalide, 
and 2, 0.8, and 1 % ginkgolides A, B, and 
C, respectively) was purchased in powdered 
pill form from Rite-Aid pharmacy 
(Washington, D.C.). Purified ginkolides A 
and B, taurine, ADP, thrombin, and all 
other reagents were purchased from Sigma 
Chemicals (St. Louis, MO). 
Platelet supply and cell adjustment 
Donor plasma units were obtained 
from Walter Reed Army Medical Center 
under a protocol approved by the 
Institutional Review Board. Plasma (101 
mL containing approximately 17 mL ACD-
A anticoagulant) was frozen at -70°e. At 
the time of experiments plasma was rapidly 
thawed at 37°C and processed for STA 
Compact coagulation assay. For all other 
assays, unfrozen, unthawed, day one (post-
donation) Platelet Rich Plasma (PRP) was 
used. Units were kept under standard blood 
banking conditions (22°C with rotation) 
until testing. PRP cell count was performed 
on an automated cell counter (Cell-Dyne 
1700, Abbott Diagnostics Division, 
Mountain View, CA) and later adjusted to 
300 x 103 cells/uL with HEPES-buffered 
platelet-poor plasma (PPP). PPP was 
prepared by centrifugation of PRP at 3000 
x g for 20 minutes at 22°C. HEPES buffer 
(137 mM NaCl, 2.7 mM KCI, 1mM MgClb 
5.6 mM glucose, and 3.8 mM HEPES, 
pH7.4) was added to PPP for a final 
concentration of .0152 HEPES (%vol.) 
Stock Solution Premaration 
Powdered G. iloba extract was 
partially dissolved in Ix Phosphate-
Buffered Saline and filtered through a 20 
mosmol porosity hypodermic syringe filter 
to a final concentration of 1000 mg/mL. 
Ginkgolides A and B were partially 
dissolved in Ix PBS and placed in an 
ultrasound water bath for complete 
dissolution to a final concentration of 1000 
mg/mL. Taurine was dissolved in Ix PBS 
and adjusted to a concentration of 250 mM. 
Solution Incubation and sample hreoaration 
PRP was incubated 10:1 wit EGb 761 
and ginkgolides (final concentration 100 
mg/mL), and 10: 1 and 50: 1 with taurine 
(25 mM, 5 mM final concentrations, 
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respectively) at 37°C for 1 hour. Cell count 
of incubated PRP was then adjusted to 300 
x 103 cells/ul with HEPES-buffered PPP. 
Based on initial PRP cell count, EGb 761, 
ginkgolides A and B, and taurine stock 
solutions were added to HEPES-buffered 
PPP before dilution in order to retain their 
respective concentrations in solution. 
Clotting Time 
Platelet samples were stimulated with 
various agonist-induced clotting tests and 
other measures of platelet viability. In vitro 
testing of coagulation was measured using 
the SPA Compact electromechanical clot 
detection system (Chronolog, Havertown, 
PA). All assays were carried out according 
to standard procedures developed by 
American Bioproducts. The following 
measures of the extrinsic clotting cascade 
were measured: Prothrombin Time (PT)-
a mixture of thromboplastin with calcium is 
added to citrated plasma, Activated Partial 
Thromboplastin Time-involves the 
recalcification time of plasma in the 
presence of a standardized amount of 
cephalin and activator silica, and Thrombin 
Time (TT)-in the presence of 0.5 u/ml 
thrombin, plasma will consistently clot in a 
finite time unless there is insufficient or 
abnormal fibrin formation. Taurine was 
prepared in 5 and 25 mM concentrations 
in plasma. 
Extent of Platelet Shape Change induced by 
ADP and Hypotonic Shock Response 
Extent of ADP-induced platelet Shape 
Change (ESC) and osmotic Hypotonic 
Shock Response (HSR) was measured as 
the change in optical density of the reaction 
mixture using the SPA-2000 instrument 
(Chronolog, Havertown, PA). The sample 
contained EDTA (2 mM final 
concentration) to prevent aggregation. ADP 
(0.02 mM final concentration) induces 
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platelet shape change from discoid to 
spherical shape with pseudepodial 
projections, causing an increase in optical 
density. The difference is computed 
automatically and given as a percentage. 
Duplicate measurements were compiled 
from five donors. 
Platelet aggregation by thrombin 
1.0 u/mL thrombin-induced 
aggregation was performed and monitored 
with a luminescent aggregometer 
(Chronolog, Havertown, PA), also utilizing 
change in optical density as an indication of 
platelet response. Aggregation results were 
measured as a percentage of maximum 
light transmittance as determined by PPP. 
Using AGGRP/LINK software, the slope 
(S) and amplitude (A) of the generated 
curves were computed. Duplicate 
measurements were compiled from 
five donors. 
Thrombelastography 
To gain a better understanding of the 
additive's effects on hemostasis as a whole, 
thrombelastograpy (TEG), which measures 
the kinetic changes associated with clotting 
and clot retraction, was performed on the 
TEG Coagulation Analyzer 5000 
(Haemoscope, Skokie, IL). A normal 
thrombelastographic tracing with associated 
values is represented in Fig. 3. Disposable 
cups and pins were used in accordance with 
manufacturer guidelines. Coagulation was 
induced by thrombin (0.6 U/mL final 
concentration) and CaCl2 (6.25 mM final 
concentration) While thrombelstagraphic 
tracings evaluate many aspects of platelet 
response, Maximum Amplitude (MA) 
and R time were focused on in this 
experiment. Duplicate runs were 
compiled from five donors. 
Figure 3. Diagrammatic thrombelastographic 
tracing 20 
Stastical Analysis 
Width of the tracing in 
millimeters is proportional 
to the elastic sheer 
modulus produced when 
the sample clots. Five 
standard measurements 
can be extrapolated from 
the tracing: 
R value distance 
from addition of agonist 
to initial clot formation 
K value- distance 
from 1 mm to 20 mm 
wide curve 
_- angle (in degrees) 
from the enter line of 
the curve to a line 
running from 1 mm point 
tangential to the curve 
Maximum Amplitude 
(MA)-maximum width 
of the curve 
A6o - width of curve at 
60 minutes (or 60 
minutes after MA) 
Mean values ±SE are shown 
throughout this report. Statistical 
significance of differences between means 
was calculated using a paired t test analysis 
(MINITAB software, Minitab Inc., State 
College, PA). P values are expressed at the 
95% confidence level (P>0.05) 
Results 
Effect of EGb 761 and Ginkgolides A and B 
EGb 761 and ginkgolides A and B 
exhibited no significant effect on ADP-
induced shape change, and little to no effect 
on hypotonic shock response of platelet 
samples (Fig. 4). Similarly, EGb 761 and its 
respective ginkgolides had no observable 
effect on lumi-aggregation (Fig. 5). 
Ginkgolide B, the most potent inhibitor of 
aggregation response based on current 
literature, is shown as indicative of this null 
response. No significant effect was 
observed on thrombelastography and 
plasma clotting times. 
Figure 4. Effects of Ginkgo biloba and ginkgolides A 
and B on ADP-induced Extent of Shape Change 
and Hypotonic Shock 
100 
Extent of Shape Change (ESC)I 
Hypotonic Shock Response 
(HSR) 
o ... 
Control EGb 761 GA GS 
SarnplalD 
EffilESC 
IIBHSR 
Figure 5. Effect of ginkolide B on thrombin-
induced lumi-aggregation. 
Taurine 
Taurine also had no significant effect 
on ADP-induced shape change (Fig. 6). 
ESC for control platelets was 30.02% ± 
6.81, while ESC for platelets incubated 
with 5 and 25 mM taurine was 28.85% ± 
4.64 and 33.57 ± 4.9, respectively. Both 
values were not statically different from 
the control. 
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Figure 6. Effect of taurine on ADP-induced Extent 
of Shape Chan2e. 
Control 5mM Taurine 25mM Taurine 
Taurine exhibited significant inhibition 
of platelet aggregation in lumi-aggregation 
(Fig. 7). Aggregation of control platelets is 
characterized by A = 94% and S = 119.25 
mM taurine displayed notable decrease in 
amplitude, with A = 81 % and S = 114. 5 
mM taurine displayed a similar 10% 
reduction in aggregation response, 
indicating a saturating effect and a lack of 
dose-dependence inhibition in 
concentrations greater than 5 mM. 
Figure 7. Effects of taurine on thrombin-induced 
Inmi-aggregation: A. Effect of taurine 
concentration on inhibition response. 
B. Representative 25 mM taurine tracing 
exhibiting aggregation inhibition. 
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B. 
While taurine produced an increase in 
time of initial clot formation (R), overall 
clot viability (MA) was unaffected. Control 
MA = 73.95 ± 2.30 mm, while 25 mM 
taurine produced a stastically insignificant 
decrease with an MA = 72.60 ± 2.60 mm. 
This effect is observable in figure 8. 
Figure 8. Thrombelastographic effects of 25 mM 
taurine on thrombin-induced aggregation. 
Results of plasma clotting tests are 
presented in figure 9. A significant increase 
of TT was observed at 25 mM 
concentration, prolonging TT by 9%. While 
this observation is stastically significant, 
(P<0.05), it is not clinically significant, as 
the data obtained still falls in the normal TT 
range. PT and APTT remained unaffected 
by taurine. 
Figure 9. Effect of taurine on plasma clotting time. 
c::J Control 
_ 25mM Taurine 
J 
Discussion 
Although several studies have 
demonstrated inhibition of platelet 
aggregation by G. biloba and taurine, none 
have used thrombelastography as a 
comparative hemostatic measurement. The 
results obtained support those present in the 
literature, as EGb 761 and ginkgolides A 
and B had no effect on ADP or thrombin-
induced aggregation. These findings support 
the specificity of G. biloba's anticoagulant 
action, which purportedly acts by inhibiting 
Platelet Activating Factor and coagulation 
induced by oxidative-stress. The slight 
decrease in HSR produced by EGb 761 is 
more an indication of faulty reagent 
preparation than osmoregulatory action. As 
the only readily obtainable form of EGb 761 
was the pill form, cellulose and other 
pharmaceutical additives prevented 
dissolution in PBS, and filtration was 
necessary to prevent hyperosmotic 
conditions that might have effected 
aggregation studies. The filtration procedure 
was obviously not successful, and future 
studies would warrant obtaining EGb 761 in 
hydrophilic liquid form to prevent such 
sources of error. Ginkgolides A and B, 
which did dissolve in PBS after ultrasound 
treatment, did not show any significant 
change in osmoregulatory response. 
While Taurine also exhibited a null 
effect on ADP-induced shape change 
(Fig.6), it did inhibit thrombin-induced 
lumi-aggregation by 10% (Fig. 7). 
Increasing concentration from 5 to 25 mM 
did not contribute to further augmentation 
of the inhibitory effect. It has been assumed 
that taurine's inhibitory action on platelet 
aggregation can be attributed to its 
regulation of intracellular Ca2+ movement. 
It has been postulated that platelet shape 
change is mediated by both calcium 
dependent and independent pathways.21 
When agonist-induced cytosolic Ca2+ 
increases were prevented by a cytosolic 
Ca2+ chelator, platelets still underwent shape 
change. Thus it is possible that in the 
presence of taurine ESC remains 
unchanged as calcium independent 
pathways compensate for its inhibitory 
action on intracellular translocation. 
Thrombelastographic analysis revealed 
a significant decrease in R value distance, 
which is associated with initial clot 
formation, while MA value remained 
unaffected. This indicates an initial 
inhibition of platelet response being 
eventually counteracted by other plasma 
coagulation elements. MA represents the 
maximum clot elastic shear modulus of the 
developed clot, and is an indication of the 
interaction between platelets and fibrin 
strands. Initial clot formation was mildly 
inhibited while overall clot viability 
remained unaffected. As MA represents an 
integral function of several hemostatic 
elements, the 10% reduction in thrombin-
induced platelet aggregation observed in 
lumi-aggregation tests is not enough to 
significantly impact the overall strength of 
the clot. 
Taurine was found to have a marginal 
effect on TT, while leaving PT and APTT 
unaffected (Figure 9). The minor effect on 
TT is not clinically significant, as TT 
remained within the normal range. Due to 
the lack of a significant impact on the 
clotting tests taurine cannot be considered 
an anticoagulant. However, due to its 
statistically significant effect on TT it may 
be pictured as a TT regulator during 
conditions of hypothermia when its 
concentration in plasma profoundly 
increases. Interestingly, Ahmad et al. report 
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prolongation of several clotting tests but no 
change in TT during hibernation in frogs, 
indicating that there is no significant 
decrease in the plasma fibrinogen level. 19 
Boral et al. even reported an increased 
plasma fibrinogen level of blood in the 
hibernating toad.21 
It can be inferred from these results 
and the results obtained that taurine 
regulates IT by modifying the sensitivity of 
the Ca2+ binding site of fibrinogen to Ca2+. 
Ca2+ ions are known to accelerate 
polymerization of fibrin monomers, and it 
has been recently shown that the function 
of the polymerization site depends on the 
structural integrity of its nearby Ca2+ site.23 
It is suggested that taurine acts by 
modifying the sensitivity of the Ca2+ 
binding site of fibrinogen to Ca2+, thus 
indirectly impairing polymerization. The 
result is a slight prolongation of TT that 
may be of a special importance under 
hypothermic conditions or conditions of 
elevated fibrinogen levels. 
It is not clear yet what mechanisms are 
at work in hibernating animals that are able 
to sustain sluggish blood flow without risk 
of microvascular blockade, however this 
research supports taurine as a probable 
hemostatic stabilizer rather than an 
anticoagulant. Increased levels of taurine in 
plasma during hibernation can be attributed 
to an increased requirement for hemostasis 
regulation and prevention of hyper-
cogulative states by modifying the Ca2+ 
binding site of fibrinogen and thus 
regulating polymerization during 
hyperthermic conditions. 
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